I reported about a study on Rifaximin a few months ago. I was not that impressed by the results at that time. Well there has been a new study released on Rifaxmin showing pretty much the same unimpressive results. The facts are still that only about 11% saw benefit over placebo. That difference seems even more dubious what with the recent placebo study showing a similar level of efficacy. Who knows if the Rifaximin is really doing anything at all? Additionally patients are only tracked for 10-weeks, there is no information for what happens after that. It appears I am not alone in my concerns regarding the study. If you check out the comments on the study you’ll find there are a few doctors chiming in with their concerns:
“Here we go on another journey into a poorly supported area of new treatment…….this article barely shows a statistically signifincant difference, and certainly not a convincing one.” – MICHAEL ELIASTAM, MD
“This study is problematic in several ways, not least of which is the long list of companies involved, and somehow attached to the trial’s outcome.” – DAVID GLUCK, MD
“As a practicing gastroenterologist for 12 years as well as an IBS sufferer for almost 40, I realized long ago that we cannot treat IBS with a pill and that IBS is for life, and not for 10 weeks. I have been following Dr. Pimental’s studies for years, and I have yet to see anything last as long as the stress and psychological manipulation techniques that I and many others have been advocating for years.” – KIMBERLY CUSATO, MD
So buyer beware, Rifaximin may not be all it’s cracked up to be or what the hype my have you believe.